Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 250Carcinoma, Non-Small-Cell Lung 86Carcinoma, Renal Cell 62Neoplasm Metastasis 53Neoplasms 51Prostatic Neoplasms 35Lung Neoplasms 32Uveal Melanoma 29Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Brain Neoplasms 24Colorectal Neoplasms 23Sarcoma 22Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Kidney Neoplasms 18Skin Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Urinary Bladder Neoplasms 14Triple Negative Breast Neoplasms 14Mesothelioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Recurrence 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

PROSTVAC 1Nivolumab 1Leukapheresis 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone-Sensitive Prostate Cancer × Ipilimumab × Clear all
NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡